SHANGHAI – Asia's contender in the CRISPR patent battle is now a step closer to seeing global IP claims validated. Toolgen Inc., of Seoul, South Korea had two patent applications granted by the Korea Intellectual Property Office covering genome editing using the CRISPR platform.